These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 31434957)

  • 1. Disease-specific and glucocorticoid-responsive serum biomarkers for Duchenne Muscular Dystrophy.
    Hathout Y; Liang C; Ogundele M; Xu G; Tawalbeh SM; Dang UJ; Hoffman EP; Gordish-Dressman H; Conklin LS; van den Anker JN; Clemens PR; Mah JK; Henricson E; McDonald C
    Sci Rep; 2019 Aug; 9(1):12167. PubMed ID: 31434957
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Large-scale serum protein biomarker discovery in Duchenne muscular dystrophy.
    Hathout Y; Brody E; Clemens PR; Cripe L; DeLisle RK; Furlong P; Gordish-Dressman H; Hache L; Henricson E; Hoffman EP; Kobayashi YM; Lorts A; Mah JK; McDonald C; Mehler B; Nelson S; Nikrad M; Singer B; Steele F; Sterling D; Sweeney HL; Williams S; Gold L
    Proc Natl Acad Sci U S A; 2015 Jun; 112(23):7153-8. PubMed ID: 26039989
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bone microarchitectural alterations in boys with Duchenne muscular dystrophy on long-term glucocorticoid treatment.
    Tung JY; Lam TP; Chan SH
    J Bone Miner Metab; 2021 Jul; 39(4):606-611. PubMed ID: 33400004
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Skeletal disproportion in glucocorticoid-treated boys with Duchenne muscular dystrophy.
    Kao KT; Joseph S; Capaldi N; Brown S; Di Marco M; Dunne J; Horrocks I; Shepherd S; Ahmed SF; Wong SC
    Eur J Pediatr; 2019 May; 178(5):633-640. PubMed ID: 30762116
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluating RANKL and OPG levels in patients with Duchenne muscular dystrophy.
    Akhtar Ali S; Kang H; Olney R; Ramos-Platt L; Ryabets-Lienhard A; Cheung C; Georgia S; Pitukcheewanont P
    Osteoporos Int; 2019 Nov; 30(11):2283-2288. PubMed ID: 31392399
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-Inflammatory and General Glucocorticoid Physiology in Skeletal Muscles Affected by Duchenne Muscular Dystrophy: Exploration of Steroid-Sparing Agents.
    Herbelet S; Rodenbach A; Paepe B; De Bleecker JL
    Int J Mol Sci; 2020 Jun; 21(13):. PubMed ID: 32605223
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Non-Invasive Biomarkers for Duchenne Muscular Dystrophy and Carrier Detection.
    Anaya-Segura MA; García-Martínez FA; Montes-Almanza LA; Díaz BG; Avila-Ramírez G; Alvarez-Maya I; Coral-Vazquez RM; Mondragón-Terán P; Escobar-Cedillo RE; García-Calderón N; Vazquez-Cardenas NA; García S; López-Hernandez LB
    Molecules; 2015 Jun; 20(6):11154-72. PubMed ID: 26091074
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vamorolone trial in Duchenne muscular dystrophy shows dose-related improvement of muscle function.
    Hoffman EP; Schwartz BD; Mengle-Gaw LJ; Smith EC; Castro D; Mah JK; McDonald CM; Kuntz NL; Finkel RS; Guglieri M; Bushby K; Tulinius M; Nevo Y; Ryan MM; Webster R; Smith AL; Morgenroth LP; Arrieta A; Shimony M; Siener C; Jaros M; Shale P; McCall JM; Nagaraju K; van den Anker J; Conklin LS; Cnaan A; Gordish-Dressman H; Damsker JM; Clemens PR;
    Neurology; 2019 Sep; 93(13):e1312-e1323. PubMed ID: 31451516
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glucocorticoid corticosteroids for Duchenne muscular dystrophy.
    Manzur AY; Kuntzer T; Pike M; Swan A
    Cochrane Database Syst Rev; 2008 Jan; (1):CD003725. PubMed ID: 18254031
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term effects of glucocorticoids on function, quality of life, and survival in patients with Duchenne muscular dystrophy: a prospective cohort study.
    McDonald CM; Henricson EK; Abresch RT; Duong T; Joyce NC; Hu F; Clemens PR; Hoffman EP; Cnaan A; Gordish-Dressman H;
    Lancet; 2018 Feb; 391(10119):451-461. PubMed ID: 29174484
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of glucocorticoids and idebenone on respiratory function in patients with duchenne muscular dystrophy.
    Buyse GM; Goemans N; van den Hauwe M; Meier T
    Pediatr Pulmonol; 2013 Sep; 48(9):912-20. PubMed ID: 23129412
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identifying evidence of cardio-renal syndrome in patients with Duchenne muscular dystrophy using cystatin C.
    Villa CR; Kaddourah A; Mathew J; Ryan TD; Wong BL; Goldstein SL; Jefferies JL
    Neuromuscul Disord; 2016 Oct; 26(10):637-642. PubMed ID: 27542440
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum pharmacodynamic biomarkers for chronic corticosteroid treatment of children.
    Hathout Y; Conklin LS; Seol H; Gordish-Dressman H; Brown KJ; Morgenroth LP; Nagaraju K; Heier CR; Damsker JM; van den Anker JN; Henricson E; Clemens PR; Mah JK; McDonald C; Hoffman EP
    Sci Rep; 2016 Aug; 6():31727. PubMed ID: 27530235
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Validation of Chemokine Biomarkers in Duchenne Muscular Dystrophy.
    Ogundele M; Zhang JS; Goswami MV; Barbieri ML; Dang UJ; Novak JS; Hoffman EP; Nagaraju K; Cinrg-Dnhs Investigators ; Hathout Y
    Life (Basel); 2021 Aug; 11(8):. PubMed ID: 34440571
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of Metabolic Biomarkers for Duchenne Muscular Dystrophy within a Natural History Study.
    Boca SM; Nishida M; Harris M; Rao S; Cheema AK; Gill K; Seol H; Morgenroth LP; Henricson E; McDonald C; Mah JK; Clemens PR; Hoffman EP; Hathout Y; Madhavan S
    PLoS One; 2016; 11(4):e0153461. PubMed ID: 27082433
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Administration of glucocorticoids in boys with Duchenne muscular dystrophy.
    Gutierrez A; England JD
    Continuum (Minneap Minn); 2013 Dec; 19(6 Muscle Disease):1703-8. PubMed ID: 24305455
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum biomarkers associated with baseline clinical severity in young steroid-naïve Duchenne muscular dystrophy boys.
    Dang UJ; Ziemba M; Clemens PR; Hathout Y; Conklin LS; ; Hoffman EP
    Hum Mol Genet; 2020 Aug; 29(15):2481-2495. PubMed ID: 32592467
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glucocorticoid corticosteroids for Duchenne muscular dystrophy.
    Manzur AY; Kuntzer T; Pike M; Swan A
    Cochrane Database Syst Rev; 2004; (2):CD003725. PubMed ID: 15106215
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The L-arginine/NO pathway and homoarginine are altered in Duchenne muscular dystrophy and improved by glucocorticoids.
    Hörster I; Weigt-Usinger K; Carmann C; Chobanyan-Jürgens K; Köhler C; Schara U; Kayacelebi AA; Beckmann B; Tsikas D; Lücke T
    Amino Acids; 2015 Sep; 47(9):1853-63. PubMed ID: 26066683
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum biomarkers of glucocorticoid response and safety in anti-neutrophil cytoplasmic antibody-associated vasculitis and juvenile dermatomyositis.
    Conklin LS; Merkel PA; Pachman LM; Parikh H; Tawalbeh S; Damsker JM; Cuthbertson DD; Morgan GA; Monach PA; Hathout Y; Nagaraju K; van den Anker J; McAlear CA; Hoffman EP
    Steroids; 2018 Dec; 140():159-166. PubMed ID: 30352204
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.